01 8Dexilant
Main Therapeutic Indication : Gastrointestinal Disorders
Currency : USD
2019 Revenue in Millions : 579
2018 Revenue in Millions : 638
Growth (%) : -9
Main Therapeutic Indication : Gastrointestinal Disorders
Currency : USD
2020 Revenue in Millions : 553
2019 Revenue in Millions : 591
Growth (%) : -6
Main Therapeutic Indication : Gastrointestinal Disorders
Currency : USD
2021 Revenue in Millions : 441
2020 Revenue in Millions : 531
Growth (%) : -10
Main Therapeutic Indication : Gastrointestinal Diseases
Currency : USD
2022 Revenue in Millions : 507
2021 Revenue in Millions : 441
Growth (%) : 15
Main Therapeutic Indication : Gastrointestinal Diseases
Currency : USD
2023 Revenue in Millions : 344
2022 Revenue in Millions : 507
Growth (%) : -23
Main Therapeutic Indication : Gastrointestinal Disorders
Currency : USD
2016 Revenue in Millions : 590
2015 Revenue in Millions : 663
Growth (%) : -11
Main Therapeutic Indication : Gastrointestinal Disorders
Currency : USD
2017 Revenue in Millions : 650
2016 Revenue in Millions : 629
Growth (%) : 3
Main Therapeutic Indication : Gastrointestinal Disorders
Currency : USD
2018 Revenue in Millions : 617
2017 Revenue in Millions : 609
Growth (%) : 1%
LOOKING FOR A SUPPLIER?